Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ma, Jun ^a   Yang, Jie ^b   Wang, Chao ^a   Zhang, Nan ^a   Dong, Ying ^a   Wang, Chengjie ^a   Wang, Yu ^a   Lin, Xinjian ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; EMODIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PLATINUM; REACTIVE OXYGEN METABOLITE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY ADENOCARCINOMA; TUMOR GROWTH; TUMOR VOLUME; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EMODIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84931464340     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/107671     Document Type: Article

References (25)

1. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013, " CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
2. R. Agarwal and S. B. Kaye, "Ovarian cancer: strategies for overcoming resistance to chemotherapy, " Nature Reviews Cancer, vol. 3, no. 7, pp. 502-516, 2003.
3. C. Marchetti, C. Pisano, G. Facchini et al., "First-line treatment of advanced ovarian cancer: current research and perspectives, " Expert Review of Anticancer Therapy, vol. 10, no. 1, pp. 47-60, 2010.
4. P. Dinh, P. Harnett, M. J. Piccart-Gebhart, and A. Awada, "New therapies for ovarian cancer: cytotoxics and molecularly targeted agents, " Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 103-112, 2008.
5. X. Lin, H.-K. Kim, and S. B. Howell, "The role of DNA mismatch repair in cisplatin mutagenicity, " Journal of Inorganic Biochemistry, vol. 77, no. 1-2, pp. 89-93, 1999.
6. X. Shang, X. Lin, G. Manorek, and S. B. Howell, "Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1, " Molecular Pharmacology, vol. 83, no. 1, pp. 85-94, 2013.
7. M.M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role of ATP-dependent transporters, " Nature Reviews Cancer, vol. 2, no. 1, pp. 48-58, 2002.
8. X.-J. Liang, D.-W. Shen, S. Garfield, and M. M. Gottesman, "Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines, " Cancer Research, vol. 63, no. 18, pp. 5909-5916, 2003.
9. T. Iida, H. Kijima, Y. Urata et al., "Hammerhead ribozyme against γ-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins, " Cancer Gene Therapy, vol. 8, no. 10, pp. 803-814, 2001.
10. G. L. Beretta, V. Benedetti, G. Cossa et al., "Increased levels and defective glycosylation ofMRPs in ovarian carcinoma cells resistant to oxaliplatin, " Biochemical Pharmacology, vol. 79, no. 8, pp. 1108-1117, 2010.
11. H. Pelicano, D. Carney, and P. Huang, "ROS stress in cancer cells and therapeutic implications, " Drug Resistance Updates, vol. 7, no. 2, pp. 97-110, 2004.
12. J. Cai, X. Niu, Y. Chen et al., "Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis, " Neoplasia, vol. 10, no. 1, pp. 41-51, 2008.
13. J. Yi, J. Yang, R. He et al., "Emodin enhances arsenic trioxideinduced apoptosis via generation of reactive oxygen species and inhibition of survival signaling, " Cancer Research, vol. 64, no. 1, pp. 108-116, 2004.
14. W. Wang, Y.-P. Sun, X.-Z. Huang et al., "Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation, " Biochemical Pharmacology, vol. 79, no. 8, pp. 1134-1140, 2010.
15. Y. Zhou, H. Chen, and Q. Yang, "Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance, " Zhonghua Yi Xue Za Zhi, vol. 76, no. 9, pp. 680-683, 1996.
16. K. Sinha, J. Das, P. B. Pal, and P. C. Sil, "Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis, " Archives of Toxicology, vol. 87, no. 7, pp. 1157-1180, 2013.
17. M. Berndtsson, M. Hägg, T. Panaretakis, A. M. Havelka, M. C. Shoshan, and S. Linder, "Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA, " International Journal of Cancer, vol. 120, no. 1, pp. 175-180, 2007.
18. Y.-I. Yang, J.-H. Kim, K.-T. Lee, and J.-H. Choi, "Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species, " Gynecologic Oncology, vol. 123, no. 3, pp. 588-596, 2011.
19. X.-Z. Huang, J. Wang, C. Huang et al., "Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1, " Cancer Biology and Therapy, vol. 7, no. 3, pp. 468-475, 2008.
20. H. Kamei, T. Koide, T. Kojima, Y. Hashimoto, and M. Hasegawa, "Inhibition of cell growth in culture by quinones, " Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 3, pp. 185-188, 1998.
21. M. M. Shi, A. Kugelman, T. Iwamoto, L. Tian, and H. J. Forman, "Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells, "The Journal of Biological Chemistry, vol. 269, no. 42, pp. 26512-26517, 1994.
22. T. M. Buttke and P. A. Sandstrom, "Oxidative stress as a mediator of apoptosis, " Immunology Today, vol. 15, no. 1, pp. 7-10, 1994.
23. S. Singh, A. R. Khan, and A. K. Gupta, "Role of glutathione in cancer pathophysiology and therapeutic interventions, " Journal of Experimental Therapeutics and Oncology, vol. 9, no. 4, pp. 303-316, 2012.
24. T. Ishikawa and F. Ali-Osman, "Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of glutathione-platinum complex and its biological significance, " The Journal of Biological Chemistry, vol. 268, no. 27, pp. 20116-20125, 1993.
25. P. Borst, R. Evers, M. Kool, and J. Wijnholds, "A family of drug transporters: the multidrug resistance-associated proteins, " Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1295-1302, 2000.